Regeneron Pharmaceuticals, Inc. (REGN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Eli Lilly & Co.

Vertex Pharmaceuticals, Inc.

Zoetis, Inc.

Bristol Myers Squibb Co.

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Johnson & Johnson

AbbVie, Inc.

Merck & Co., Inc.

Seagen Inc.

Horizon Therapeutics Plc

Why is Regeneron Pharmaceuticals, Inc. ?

High Management Efficiency with a high ROE of 23.74%

The company is Net-Debt Free

Healthy long term growth as Net Sales has grown by an annual rate of 11.04% and Operating profit at 0.69%

Flat results in Mar 26

INTEREST(HY) At USD 25.1 MM has Grown at 30.73%
ROCE(HY) Lowest at 14.55%
OPERATING PROFIT MARGIN(Q) Lowest at 24.07 %

With ROE of 13.93%, it has a attractive valuation with a 3.24 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 19.05%, its profits have fallen by -2.4% ; the PEG ratio of the company is 10.8

High Institutional Holdings at 90.81%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 1.72% over the previous quarter.

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Regeneron Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Regeneron Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Regeneron Pharmaceuticals, Inc.

19.05%

-1.16

33.30%

S&P 500

22.99%

1.78

12.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.04%

EBIT Growth (5y)

0.69%

EBIT to Interest (avg)

87.72

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.22

Sales to Capital Employed (avg)

0.45

Tax Ratio

9.73%

Dividend Payout Ratio

8.49%

Pledged Shares

Institutional Holding

90.81%

ROCE (avg)

33.12%

ROE (avg)

23.74%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.24

EV to EBIT

25.58

EV to EBITDA

22.31

EV to Capital Employed

3.84

EV to Sales

6.60

PEG Ratio

10.77

Dividend Yield

0.38%

ROCE (Latest)

15.01%

ROE (Latest)

13.93%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 5,012.7 MM

DIVIDEND PAYOUT RATIO(Y)

Highest at 13.92%

INVENTORY TURNOVER RATIO(HY)

Highest at 0.9 times

DEBTORS TURNOVER RATIO(HY)

Highest at 2.64 times

DIVIDEND PER SHARE(HY)

Highest at USD 2.64

-10What is not working for the Company

INTEREST(HY)

At USD 25.1 MM has Grown at 30.73%

ROCE(HY)

Lowest at 14.55%

OPERATING PROFIT MARGIN(Q)

Lowest at 24.07 %

PRE-TAX PROFIT(Q)

At USD 909.1 MM has Fallen at -28.6%

NET PROFIT(Q)

At USD 795.35 MM has Fallen at -26.94%

EPS(Q)

Lowest at USD 6.75

Here's what is working for Regeneron Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 5,012.7 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Inventory Turnover Ratio

Highest at 0.9 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 2.64 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Dividend per share

Highest at USD 2.64

in the last five years

MOJO Watch

Company is distributing higher dividend from profits generated

DPS (USD)

Dividend Payout Ratio

Highest at 13.92%

in the last five years

MOJO Watch

Company is distributing higher proportion of profits generated as dividend

DPR (%)

Here's what is not working for Regeneron Pharmaceuticals, Inc.

Interest

At USD 25.1 MM has Grown at 30.73%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit Margin

Lowest at 24.07 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

At USD 909.1 MM has Fallen at -28.6%

over average net sales of the previous four periods of USD 1,273.25 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 795.35 MM has Fallen at -26.94%

over average net sales of the previous four periods of USD 1,088.66 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD 6.75

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)